# Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

> **NCT03709082** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Kansas Medical Center** · enrollment: 3 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Breast Cancer Metastatic

## Interventions

- **DRUG:** Palbociclib 75mg
- **DRUG:** Letrozole 2.5mg
- **DRUG:** T-DM1
- **DRUG:** Palbociclib 100mg
- **DRUG:** Palbociclib 125mg
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT03709082
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-15
- **Primary completion:** 2020-03-12
- **Final completion:** 2021-02-03
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2024-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03709082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03709082, "Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03709082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*